Advertisement
JOGC

The Management of Uterine Leiomyomas

      Abstract

      Objectives

      The aim of this guideline is to provide clinicians with an understanding of the pathophysiology, prevalence, and clinical significance of myomata and the best evidence available on treatment modalities.

      Options

      The areas of clinical practice considered in formulating this guideline were assessment, medical treatments, conservative treatments of myolysis, selective uterine artery occlusion, and surgical alternatives including myomectomy and hysterectomy. The risk-to-benefit ratio must be examined individually by the woman and her health care provider.

      Outcomes

      Implementation of this guideline should optimize the decision-making process of women and their health care providers in proceeding with further investigation or therapy for uterine leiomyomas, having considered the disease process and available treatment options, and reviewed the risks and anticipated benefits.

      Evidence

      Published literature was retrieved through searches of PubMed, CINAHL, and Cochrane Systematic Reviews in February 2013, using appropriate controlled vocabulary (uterine fibroids, myoma, leiomyoma, myomectomy, myolysis, heavy menstrual bleeding, and menorrhagia) and key words (myoma, leiomyoma, fibroid, myomectomy, uterine artery embolization, hysterectomy, heavy menstrual bleeding, menorrhagia). The reference lists of articles identified were also searched for other relevant publications. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date limits but results were limited to English or French language materials. Searches were updated on a regular basis and incorporated in the guideline to January 2014. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology-related agencies, clinical practice guideline collections, and national and international medical specialty societies.

      Benefits, Harms, and Costs

      The majority of fibroids are asymptomatic and require no intervention or further investigations. For symptomatic fibroids such as those causing menstrual abnormalities (e.g. heavy, irregular, and prolonged uterine bleeding), iron defficiency anemia, or bulk symptoms (e.g., pelvic pressure/pain, obstructive symptoms), hysterectomy is a definitive solution. However, it is not the preferred solution for women who wish to preserve fertility and/or their uterus. The selected treatment should be directed towards an improvement in symptomatology and quality of life. The cost of the therapy to the health care system and to women with fibroids must be interpreted in the context of the cost of untreated disease conditions and the cost of ongoing or repeat investigative or treatment modalities.

      Values

      The quality of evidence in this document was rated using the criteria described in the Report of the Caadian Task Force on Preventive Health Care (Table 1).

      Summary Statements

      • 1.
        Uterine fibroids are common, appearing in 70% of women by age 50; the 20% to 50% that are symptomatic have considerable social and economic impact in Canada. (II-3)
      • 2.
        The presence of uterine fibroids can lead to a variety of clinical challenges. (III)
      • 3.
        Concern about possible complications related to fibroids in pregnancy is not an indication for myomectomy except in women who have had a previous pregnancy with complications related to these fibroids. (III)
      • 4.
        Women who have fibroids detected in pregnancy may require additional maternal and fetal surveillance. (II-2)
      • 5.
        Effective medical treatments for women with abnormal uterine bleeding associated with uterine fibroids include the levonorgestrel intrauterine system, (I) gonadotropin-releasing hormone analogues, (I) selective progesterone receptor modulators, (I) oral contraceptives, (II-2) progestins, (II-2) and danazol. (II-2)
      • 6.
        Effective medical treatments for women with bulk symptoms associated with fibroids include selective progesterone receptor modulators and gonadotropin-releasing hormone analogues. (I)
      • 7.
        Hysterectomy is the most effective treatment for symptomatic uterine fibroids. (III)
      • 8.
        Myomectomy is an option for women who wish to preserve their uterus or enhance fertility, but carries the potential for further intervention. (II-2)
      • 9.
        Of the conservative interventional treatments currently available, uterine artery embolization has the longest track record and has been shown to be effective in properly selected patients. (II-3)
      • 10.
        Newer focused energy delivery methods are promising but lack long-term data. (III)

      Recommendations

      • 1.
        Women with asymptomatic fibroids should be reassured that there is no evidence to substantiate major concern about malignancy and that hysterectomy is not indicated. (III-D)
      • 2.
        Treatment of women with uterine leiomyomas must be individualized based on symptomatology, size and location of fibroids, age, need and desire of the patient to preserve fertility or the uterus, the availability of therapy, and the experience of the therapist. (III-B)
      • 3.
        In women who do not wish to preserve fertility and/or their uterus and who have been counselled regarding the alternatives and risks, hysterectomy by the least invasive approach possible may be offered as the definitive treatment for symptomatic uterine fibroids and is associated with a high level of satisfaction. (II-2A)
      • 4.
        Hysteroscopic myomectomy should be considered first-line conservative surgical therapy for the management of symptomatic intracavitary fibroids. (II-3A)
      • 5.
        Surgical planning for myomectomy should be based on mapping the location, size, and number of fibroids with the help of appropriate imaging. (III-A)
      • 6.
        When morcellation is necessary to remove the specimen, the patient should be informed about possible risks and complications, including the fact that in rare cases fibroid(s) may contain unexpected malignancy and that laparoscopic power morcellation may spread the cancer, potentially worsening their prognosis. (III-B)
      • 7.
        Anemia should be corrected prior to proceeding with elective surgery. (II-2A) Selective progesterone receptor modulators and gonadotropin-releasing hormone analogues are effective at correcting anemia and should be considered preoperatively in anemic patients. (I-A)
      • 8.
        Use of vasopressin, bupivacaine and epinephrine, misoprostol, peri-cervical tourniquet, or gelatin-thrombin matrix reduce blood loss at myomectomy and should be considered. (I-A)
      • 9.
        Uterine artery occlusion by embolization or surgical methods may be offered to selected women with symptomatic uterine fibroids who wish to preserve their uterus. Women choosing uterine artery occlusion for the treatment of fibroids should be counselled regarding possible risks, including the likelihood that fecundity and pregnancy may be impacted. (II-3A)
      • 10.
        In women who present with acute uterine bleeding associated with uterine fibroids, conservative management with estrogens, selective progesterone receptor modulators, antifibrinolytics, Foley catheter tamponade, and/or operative hysteroscopic intervention may be considered, but hysterectomy may become necessary in some cases. In centres where available, intervention by uterine artery embolization may be considered. (III-B)

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Day Baird D.
        • Dunson D.B.
        • Hill M.C.
        • Cousins D.
        • Schectman J.M.
        High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.
        Am J Obstet Gynecol. 2003; 188: 100-107
        • Marshall L.M.
        • Spiegelman D.
        • Barbieri R.L.
        • Goldman M.B.
        • Manson J.E.
        • Colditz G.A.
        • et al.
        Variation in the incidence of uterine leiomyoma among premenopausal women by age and race.
        Obstet Gynecol. 1997; 90: 967-973
        • Cramer S.F.
        • Patel A.
        The frequency of uterine leiomyomas.
        Am J Clin Pathol. 1990; 94: 435-438
        • Zimmermann A.
        • Bernuit D.
        • Gerlinger C.
        • Schaefers M.
        • Geppert K.
        Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women.
        BMC Womens Health. 2012; 12 (26 March 2012) Available at (Accessed on November 10, 2014): 6
        • Downes E.
        • Sikirica V.
        • Gilabert-Estelles J.
        • Bolge S.C.
        • Dodd S.L.
        • Maroulis C.
        • et al.
        The burden of uterine fibroids in five European countries.
        Eur J Obstet Gynecol Reprod Biol. 2010; 152: 96-102
        • Pritts E.A.
        • Parker W.H.
        • Olive D.L.
        Fibroids and infertility: an updated systematic review of the evidence.
        Fertil Steril. 2009; 91: 1215-1223
        • Vilos G.A.
        • Vilos A.
        • Ferrazzi S.
        Symptomatic uterine fibroids (UFs) are common in premenopausal Canadian women and lead to reduced quality of life (QoL) across multiple domains.
        J Obstet Gynecol Can. 2014; 36 ([abstract]): S26
        • Canadian Institute for Health Information
        Statistics Canada. Health indicators. CIHI, Ottawa2010 (Available at:) (Accessed on November 10, 2014)
        • Boyd L.R.
        • Novesky A.P.
        • Curtin J.P.
        Effect of surgical volume on route of hysterectomy and short-term morbidity.
        Obstet Gynecol. 2010; 116: 909-915
        • Clark-Pearson D.L.
        • Geller E.L.
        Complications of hysterectomy.
        Obstet Gynecol. 2013; 121: 654-673
        • Bulun S.E.
        Uterine fibroids.
        N Engl J Med. 2013; 369: 1344-1355
        • Munro M.G.
        • Critchley H.O.
        • Broder M.S.
        • Fraser I.S.
        The FIGO Classification System (“PALM-COEIN”) for causes of abnormal uterine bleeding in non-gravid women in the reproductive years, including guidelines for clinical investigation.
        Int J Gynaecol Obstet. 2011; 113: 3-13
        • Flake G.P.
        • Andersen J.
        • Dixon D.
        Etiology and pathophysiology of uterine leiomyomas; a review.
        Environ Health Perspect. 2003; 111: 1037-1054
        • Buttram V.C.
        • Reiter R.C.
        Uterine leiomyomata: etiology, symptomatology and management.
        Fertil Steril. 1981; 36: 433-445
        • Lumsden M.A.
        • Wallace E.M.
        Clinical presentation of uterine fibroids.
        Baillieres Clin Obstet Gynaecol. 1998; 12: 177-195
        • Miura S.
        • Khan K.N.
        • Kitajima M.
        • Hiraki K.
        • Moriyama S.
        • Masuzaki H.
        • et al.
        Differential infiltration of macrophages and prostaglandin by different uterine leiomyomas.
        Hum Reprod. 2006; 21: 2545-2554
        • Singh S.
        • Best C.
        • Dunn S.
        • Leyland N.
        • Wolfman W.
        Society of Obstetrics and Gynaecology Canada Clinical Practice – Gynaecology Committee. Abnormal uterine bleeding in pre-menopausal women.
        J Obstet Gynaecol Can. 2013; 35 (SOGC Clinical Practice Guidelines, No. 292, May 2013): 473-479
        • Schwartz L.B.
        • Diamond M.P.
        • Schwartz P.E.
        Leiomyosarcomas: clinical presentation.
        Am J Obstet Gynecol. 1993; 168: 180-183
        • Carranza-Mamane B.
        • Havelock J.
        • Hemmings R.
        Society of Obstetrics and Gynaecology Canada Reproductive Endocrinology and Infertility Committee. The management of uterine fibroids in women with otherwise unexplained infertility. SOGC Clinical Practice Guidelines.
        J Obstet Gynaecol Can. 2015; (in press)
        • Laughlin S.K.
        • Baird D.D.
        • Savitz D.A.
        • Herring A.H.
        • Hartmann K.E.
        Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study.
        Obstet Gynecol. 2009; 113: 630-635
        • Muram D.
        • Gillieson M.
        • Walters J.H.
        Myomas of the uterus in pregnancy: ultrasonographic follow-up.
        Am J Obstet Gynecol. 1980; 138: 16-19
        • Neiger R.
        • Sonek J.D.
        • Croom C.S.
        • Ventolini G.
        Pregnancy-related changes in the size of uterine leiomyomas.
        J Reprod Med. 2006; 51: 671-674
        • Hammoud A.O.
        • Asaad R.
        • Berman J.
        • Treadwell M.C.
        • Blackwell S.
        • Diamond M.P.
        Volume change of uterine myomas during pregnancy: do myomas really grow?.
        J Minim Invasive Gynecol. 2006; 13: 386-390
        • Laughlin S.K.
        • Herrings A.H.
        • Savitz D.A.
        • Olsham A.F.
        • Fielding J.R.
        • Hartman K.E.
        • et al.
        Pregnancy-related fibroid reduction.
        Fertil Steril. 2010; 94: 2421-2423
        • De Vivo A.
        • Mancuso A.
        • Giacobbe A.
        • Savasta L.M.
        • De Dominici R.
        • Dugo N.
        • et al.
        Uterine myomas during pregnancy: a longitudinal sonographic study.
        Ultrasound Obstet Gynecol. 2011; 37: 361-365
        • Exacoustos C.
        • Rosati P.
        Ultrasound diagnosis of uterine myomas and complications in pregnancy.
        Obstet Gynecol. 1993; 82: 97-101
        • Sheiner E.
        • Bashiri A.
        • Levy A.
        • Hershkovitz R.
        • Katz M.
        • Mazor M.
        Obstetric characteristics and perinatal outcome of pregnancies with uterine leiomyomas.
        J Reprod Med. 2004; 49: 182-186
        • Qidwai G.I.
        • Caughey A.B.
        • Jacoby A.F.
        Obstetric outcomes in women with sonographically identified uterine leiomyomata.
        Obstet Gynecol. 2006; 107: 376-382
        • Vergani P.
        • Locatelli A.
        • Ghidini A.
        • Andreani M.
        • Sala F.
        • Pezzullo J.C.
        Large uterine leiomyomata and risk of cesarean delivery.
        Obstet Gynecol. 2007; 109: 410-414
        • Chen Y.H.
        • Lin H.C.
        • Chen S.F.
        • Lin H.C.
        Increased risk of preterm births among women with uterine leiomyoma: a nationwide population-based study.
        Hum Reprod. 2009; 24: 3049-3056
        • Klatsky P.C.
        • Tran N.D.
        • Caughey A.B.
        • Fujimoto V.Y.
        Fibroids and reproductive outcomes: a systematic literature review from conception to delivery.
        Am J Obstet Gynecol. 2008; 198: 357-366
        • Stout M.J.
        • Odibo A.O.
        • Graseck A.S.
        • Macones G.A.
        • Crane J.P.
        • Cahill A.G.
        Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes.
        Obstet Gynecol. 2010; 116: 1056-1063
        • Lolis D.E.
        • Kalantaridou S.N.
        • Makrydimas G.
        • Sotiriadis A.
        • Navrozoglou I.
        • Zikopoulos K.
        • et al.
        Successful myomectomy during pregnancy.
        Hum Reprod. 2003; 18: 1699-1702
        • Mu Y.L.
        • Wang S.
        • Hao J.
        • Shi M.
        • Yelian F.D.
        • Wang X.T.
        Successful pregnancies with uterine leiomyomas and myomectomy at the time of caesarean section.
        Postgrad Med J. 2011; 87: 601-604
        • Gbadebo A.A.
        • Charles A.A.
        • Austin O.
        Myomectomy at caesarean section: descriptive study of clinical outcome in a tropical setting.
        J Ayub Med Coll Abbottabad. 2009; 21: 7-9
        • Park B.J.
        • Kim Y.W.
        Safety of cesarean myomectomy.
        J Obstet Gynaecol Res. 2009; 35: 906-911
        • Parker W.H.
        • Fu Y.S.
        • Berek J.S.
        Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
        Obstet Gynecol. 1994; 83: 414-418
        • Leibsohn S.
        • d’Ablaing G.
        • Mishell Jr., D.R.
        • Schlaerth J.B.
        Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.
        Am J Obstet Gynecol. 1990; 162 (discussion 974–6): 968-974
        • Knight J.
        • Falcone T.
        Tissue extraction by morcellation: a clinical dilemma.
        J Min Invas Gynecol. 2014; 21: 319-320
        • Vilos G.A.
        • Harding P.G.
        • Sugimoto A.K.
        • Ettler H.C.
        • Bernier M.J.
        Hysteroscopic endomyometrial resection of three uterine sarcomas.
        J Am Assoc Gynecol Laparosc. 2001; 8: 545-551
        • Vilos G.A.
        • Edris F.
        • Abu-Rafea B.
        • Hollett-Caines J.
        • Ettler H.C.
        • Al-Mubarak A.
        Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery.
        J Min Invas Gynecol. 2009; 16: 318-325
        • Ip P.P.
        • Tse K.Y.
        • Tam K.F.
        Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
        Adv Anat Pathol. 2010; 17: 91-112
        • Vilos G.A.
        • Marks J.
        • Ettler H.C.
        • Vilos A.G.
        • Prefontaine M.
        • Abu-Rafea B.
        Uterine smooth muscle tumors of uncertain malignant potential; diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of literature.
        J Min Invas Gynecol. 2012; 19: 288-295
        • Cantuaria G.H.
        • Anglioli R.
        • Frost L.
        • Duncan R.
        • Penalver M.A.
        Comparison of bimanual examination with ultrasound before hysterectomy for uterine leiomyoma.
        Obstet Gynecol. 1998; 92: 109-112
        • Farquhar C.
        • Ekeroma A.
        • Furness S.
        • Arroll B.
        A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women.
        Acta Obstet Gynecol Scand. 2003; 82: 493-504
        • Makris N.
        • Kalmantis K.
        • Startados N.
        • Papadimitriou A.
        • Mantzaris G.
        • Antsaklis A.
        Three dimensional hysterosonography versus hysteroscopy for the detection of intracavitary uterine abnormalities.
        Int J Gynecol Obstet. 2007; 95: 6-9
        • Vercellini P.
        • Crosignani P.G.
        • Mangioni C.
        • Imparato E.
        • Ferrari A.
        • De Giorgi O.
        Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: results of a multicentre, randomized controlled trial.
        Br J Obstet Gynaecol. 1998; 105: 1148-1154
        • Bradley L.D.
        • Falcone T.
        • Magen A.B.
        Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding.
        Obstet Gynecol Clin North Am. 2000; 27: 245-276
        • Adusumilli S.
        • Hussain H.K.
        • Caoili E.M.
        • Weadock W.J.
        • Murray J.P.
        • Johnson T.D.
        • et al.
        MRI of sonographically indeterminate adnexal masses.
        AJR Am J Roentgenol. 2006; 187: 732-740
        • Dueholm M.
        • Lundorf E.
        • Hansen E.S.
        • Ledertoug S.
        • Olesen F.
        Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas.
        Am J Obstet Gynecol. 2002; 186: 409-415
        • Omary R.A.
        • Vasireddy S.
        • Chrisman H.B.
        • Ryu R.K.
        • Pereles F.S.
        • Carr J.C.
        • et al.
        The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids.
        J Vasc Interv Radiol. 2002; 13: 1149-1153
        • Stamatopoulos C.P.
        • Mikos T.
        • Grimbizis G.F.
        • Dimitriadis A.S.
        • Efstratiou I.
        • Stamatopoulos P.
        • et al.
        Value of magnetic resonance imaging in diagnosis of adenomyosis and myomas of the uterus.
        J Min Invas Gynecol. 2012; 19: 620-626
        • Myers E.R.
        • Barber M.D.
        • Gustilo-Ashby T.
        • Couchman G.
        • Matchar D.B.
        • McCrory D.C.
        Management of uterine leiomyomata: what do we really know?.
        Obstet Gynecol. 2002; 100: 8-17
        • Peddada S.D.
        • Laughlin S.K.
        • Miner K.
        • Guyon J.P.
        • Haneke K.
        • Vahdat H.L.
        • et al.
        Growth of uterine leiomyomata among premenopausal black and white women.
        Proc Natl Acad Sci USA. 2008; 105: 19887-19892
        • DeWaay D.J.
        • Syrop C.H.
        • Nygaard I.E.
        • Davis W.A.
        • Van Voorhis B.J.
        Natural history of uterine polyps and leiomyomata.
        Obstet Gynecol. 2002; 100: 3-7
        • Ang W.C.
        • Farrell E.
        • Vollenhoven B.
        Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a systematic review.
        Climacteric. 2001; 4: 284-292
        • Yang C.H.
        • Lee J.N.
        • Hsu S.C.
        • Kuo C.H.
        • Tsai E.M.
        Effect of hormone replacement therapy on uterine fibroids in postmenopausal women—a 3-year study.
        Maturitas. 2002; 43: 35-39
        • Al-Hendy A.
        • Salama S.
        Gene therapy and uterine leiomyoma: a review.
        Hum Reprod Update. 2006; 12: 385-400
        • Sayed G.H.
        • Zakherah M.S.
        • El-Nashar S.A.
        • Shaaban M.M.
        A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia.
        Int J Gynaecol Obstet. 2011; 112: 126-130
        • Maruo T.
        • Ohara N.
        • Yoshida S.
        • Nakabayashi K.
        • Sasaki H.
        • Xu Q.
        • et al.
        Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.
        Contraception. 2010; 82: 435-441
        • Englund K.
        • Blanck A.
        • Gustavsson I.
        • Lundkvist U.
        • Sjöblom P.
        • Norgren A.
        • et al.
        Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment.
        J Clin Endocrinol Metab. 1998; 83 (11): 4092-4096
        • Magalhães J.
        • Aldrighi J.M.
        • de Lima G.R.
        Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
        Contraception. 2007; 75: 193-198
        • Verspyck E.
        • Marpeau L.
        • Lucas C.
        Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.
        Eur J Obstet Gynecol Reprod Biol. 2000; 89: 7-13
        • Sangkomkamhang U.S.
        • Lumbiganon P.
        • Laopaiboon M.
        • Mol B.W.
        Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.
        Cochrane Database Syst Rev. 2013; 2 (CD008994)
        • Carr B.R.
        • Marshburn P.B.
        • Weatherall P.T.
        • Bradshaw K.D.
        • Breslau N.A.
        • Byrd W.
        • et al.
        An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
        J Clin Endocrinol Metab. 1993; 76: 1217-1223
        • Friedman A.J.
        • Daly M.
        • Juneau-Norcross M.
        • Rein M.S.
        • Fine C.
        • Gleason R.
        • et al.
        A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin “add-back” regimens for women with leiomyomata uteri.
        J Clin Endocrinol Metab. 1993; 76: 1439-1445
        • Friedman A.J.
        • Hoffman D.I.
        • Comite F.
        • Browneller R.W.
        • Miller J.D.
        Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study.
        The Leuprolide Study Group. Obstet Gynecol. 1991; 77: 720-725
        • Reissmann T.
        • Diedrich K.
        • Comaru-Schally A.M.
        • Schally A.V.
        Introduction of LHRH-antagonists into the treatment of gynaecological disorders.
        Human Reprod. 1994; 9: 767-769
        • Britten J.L.
        • Malik M.
        • Levy G.
        • Mendoza M.
        • Catherino W.H.
        Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
        Fertil Steril. 2012; 98: 1299-1307
        • Panidis D.
        • Vavilis D.
        • Rousso D.
        • Stergiopoulos K.
        • Kalogeropoulos A.
        Danazol influences gonadotropin secretion acting at the hypothalamic level.
        Int J Gynaecol Obstet. 1994; 45: 241-246
        • A.C.O.G. Committee on Practice Bulletins-Gynecology
        ACOG practice bulletin: surgical alternatives to hysterectomy in the management of leiomyomas.
        Int J Gynaecol Obstet. 2001; 73: 285-294
        • Ke L.Q.
        • Yang K.
        • Li J.
        • Li C.M.
        Danazol for uterine fibroids.
        Cochrane Database Syst Rev. 2009; 3 (CD007692)
        • Sumitani H.
        • Shozu M.
        • Segawa T.
        • Murakami K.
        • Yang H.J.
        • Shimada K.
        • et al.
        In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism.
        Endocrinology. 2000; 141: 3852-3861
        • Song H.
        • Lu D.
        • Navaratnam K.
        • Shi G.
        Aromatase inhibitors for uterine fibroids.
        Cochrane Database Syst Rev. 2013; 10 (CD009505)
        • Wakeling A.E.
        • Dukes M.
        • Bowler J.
        A potent specific pure antiestrogen with clinical potential.
        Cancer Res. 1991; 51: 3867-3873
        • Donnez J.
        • Hervais Vivancos B.
        • Kudela M.
        • Audebert A.
        • Jadoul P.
        A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.
        Fertil Steril. 2003; 79: 1380-1389
        • Dutertre M.
        • Smith C.L.
        Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
        J Pharmacol Exp Ther. 2000; 295: 431-437
        • Deng L.
        • Wu T.
        • Chen X.Y.
        • Xie L.
        • Yang J.
        Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.
        Cochrane Database Syst Rev. 2012; 10 (CD005287)
        • Chegini N.
        • Ma C.
        • Tang X.M.
        • Williams R.S.
        Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression.
        Mol Hum Reprod. 2002; 8: 1071-1078
        • Maruo T.
        • Ohara N.
        • Wang J.
        • Matsuo H.
        Sex steroidal regulation of uterine leiomyoma growth and apoptosis.
        Hum Reprod Update. 2004; 10: 207-220
        • Kawaguschi K.
        • Fujii S.
        • Konishi I.
        • Nanbu Y.
        • Nonogaki H.
        • Mori T.
        Mitotic activity in uterine leiomyomas during the menstrual cycle.
        Am J Obstet Gynecol. 1989; 160: 637-641
        • Kawaguschi K.
        • Fujii S.
        • Konishi I.
        • Iwai T.
        • Nanbu Y.
        • Nonogaki H.
        • et al.
        Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy.
        Virchows Arch A Pathol Anat Histopathol. 1991; 419: 309-315
        • Seagaloff A.
        • Weed J.C.
        • Sternberg W.H.
        • Parson W.
        The progesterone therapy of human uterine leiomyomas.
        J Clin Endocrinol Metrab. 1949; 9: 1273-1291
        • Friedman A.J.
        • Daly M.
        • Juneau-Norcross M.
        • Gleason R.
        • Rein M.S.
        • LeBoff M.
        Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years.
        Hum Reprod. 1994; 9: 1618-1625
        • Chwalisz K.
        • Perez M.C.
        • Demanno D.
        • Winkel C.
        • Schubert G.
        • Elger W.
        Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
        Endocr Rev. 2005; 26: 423-438
        • Shen Q.
        • Hua Y.
        • Jiang W.
        • Zhang W.
        • Chen M.
        • Zhu X.
        Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis.
        Fertil Steril. 2013; 100: 1722-1726
        • Chabbert-Buffet N.
        • Pintiaux-Kairis A.
        • Bouchard P.
        VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.
        J Clin Endocrinol Metab. 2007; 92: 3582-3589
        • Donnez J.
        • Tatarchuk T.F.
        • Bouchard P.
        • Puscasiu L.
        • Zakharenko N.F.
        • Ivanova T.
        • et al.
        Ulipristal acetate versus placebo for fibroid treatment before surgery.
        N Engl J Med. 2012; 366: 409-420
        • Donnez J.
        • Tomaszewski J.
        • Vazquez F.
        • Bouchard P.
        • Lemieszczuk B.
        • Baro F.
        • et al.
        Ulipristal acetate versus leuprolide acetate for uterine fibroids.
        N Engl J Med. 2012; 366: 421-432
        • Donnez J.
        • Vazquez F.
        • Tomaszewski J.
        • Nouri K.
        • Bouchard P.
        • Fauser B.
        • et al.
        PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate*.
        Fertil Steril. 2014; 101: 1565-1573
        • Weber A.M.
        • Mitchinson A.R.
        • Gidwani G.P.
        • Mascha E.
        • Walters M.D.
        Uterine myomas and factors associated with hysterectomy in premenopausal women.
        Am J Obstet Gynecol. 1997; 176: 1213-1217
        • Friedman A.J.
        • Haas S.T.
        Should uterine size be an indication for surgical intervention in women with myomas?.
        Am J Obstet Gynecol. 1993; 168: 751-755
        • Lefebvre G.
        • Allaire A.
        • Jeffrey J.
        • Vilos G.
        Hysterectomy; Socoiety of Obstetricians Clinical Practice Committee.
        J Obstet Gynaecol Can. 2002; 24 (SOGC Clinical Practice Guidelines, No. 109, January 2002): 37-48
        • Thakar R.
        • Ayers S.
        • Clarkson P.
        • Stanton S.
        • Manyonda I.
        Outcomes after total versus subtotal abdominal hysterectomy.
        N Engl J Med. 2002; 347: 1318-1325
        • Learman L.A.
        • Summitt Jr., R.L.
        • Varner R.E.
        • McNeeley S.G.
        • Goodman-Gruen D.
        • Richter H.E.
        • et al.
        Total or Supracervical Hysterectomy (TOSH) Research Group. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes.
        Obstet Gynecol. 2003; 102: 453-462
        • American Association of Gynecologic Laparoscopists (AAGL)
        Practice report: practice guidelines for laparoscopic/subtotal supracervical hysterectomy.
        J Min Invas Gynecol. 2014; 21: 9-16
        • Garcia C.R.
        Management of the symptomatic fibroid in women older than 40 years of age: hysterectomy or myomectomy?.
        Obstet Gynecol Clin North Am. 1993; 20: 337-348
        • Yoo E.H.
        • Lee P.I.
        • Huh C.Y.
        • Kim D.H.
        • Lee B.S.
        • Lee J.K.
        • et al.
        Predictors of leiomyoma recurrence after laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2007; 14: 690-697
        • Al-Mahrizi S.
        • Tulandi T.
        Treatment of uterine fibroids for abnormal uterine bleeding: myomectomy and uterine artery embolization.
        Best Pract Res Clin Obstet Gynaecol. 2007; 21: 995-1005
        • Cagnacci A.
        • Pirillo D.
        • Malmusi S.
        • Arangino S.
        • Alessandrini C.
        • Volpe A.
        Early outcome of myomectomy by laparotomy, minilaparotomy and laparoscopically assisted minilaparotomy. A randomized prospective study.
        Hum Reprod. 2003; 18: 2590-2594
        • American Association of Gynecologic Laparoscopists (AAGL)
        AAGL practice report: practice guidelines for the diagnosis and management of submucous leiomyomas.
        J Minim Invasive Gynecol. 2012; 19: 152-171
        • Munro M.G.
        Abnormal uterine bleeding: surgical management – part 3.
        J Am Assoc Gynecol Laparosc. 2001; 8: 18-47
        • College National des Gynécologues et Obstétriciens Français (CNGOF)
        Actualisation de la prise en charge des myomes [Myoma management recommandations].
        J Gynecol Obstet Biol Reprod. 2011; 40: 693-708
        • Wamsteker K.
        • Emanuel M.H.
        • de Kruif J.H.
        Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension.
        Obstet Gynecol. 1993; 82: 736-740
        • Loffer F.D.
        Improving results of hysteroscopic submucusal myomectomy for menorrhagia by concomitant endometrial ablation.
        J Min Invas Gynecol. 2005; 12: 254-260
        • Emanuel M.H.
        • Wamsteker K.
        • Hart A.A.
        • Metz G.
        • Lammes F.B.
        Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding.
        Obstet Gynecol. 1999; 93: 743-748
        • Hart R.
        • Molnar B.G.
        • Magos A.
        Long-term follow-up of hysteroscopic myomectmoy assessed by survical analysis.
        Br J Obstet Gynaecol. 1999; 106: 700-705
        • Margiani R.
        • Mossa B.
        • Ebano V.
        • Perniola G.
        • Melluso J.
        • Napolitano C.
        Transcervical myomectomy: long-term effects on abnormal uterine bleeding.
        Clin Exp Obstet Gynecol. 2005; 32: 23-26
        • Bradley L.D.
        Complications in hysteroscopy: prevention, treatment and legal risk.
        Curr Opin Obstet Gynecol. 2002; 14: 409-415
        • Vilos G.A.
        • Vilos G.A.
        Chapter on hysteroscopic surgery: indications, contraindications and complications.
        in: Pasic R. Levine R.A. Practical manual of hysteroscopy and endometrial ablation: a clinical cookbook. CRC Press, Boca Raton, FL2004: 237-258
        • AAGL Advancing Minimally Invasive Gynecology Worldwide
        • Munro M.G.
        • Storz K.
        • Abbott J.A.
        • Falcone T.
        • Jacobs V.R.
        • et al.
        AAGL practice report. practice guidelines for the management of hysteroscopic distendng media.
        J Minim Invasive Gynecol. 2013; 20: 137-148
        • Vilos G.A.
        • Brown S.
        • Graham G.
        • McCulloch S.
        • Borg P.
        Genital tract electrical burns during hysteroscopic endometrial ablation: report of 13 cases in the United States and Canada.
        J Am Assoc Gynecol Laparosc. 2000; 7: 141-147
        • Vilos G.A.
        • McCulloch S.
        • Borg P.
        • Zheng W.
        • Denstedt J.
        Intended and stray radiofrequency electrical currents during resectoscopic surgery.
        J Am Assoc Gynecol Laparsc. 2000; 7: 55-63
        • Vilos G.A.
        • Newton D.W.
        • Odell R.C.
        • Abu-Rafea B.
        • Vilos A.G.
        Characterization and mitigation of stray radiofrequency currents during monopolar resectoscopic electrosurgery.
        J Minim Invasive Gynecol. 2006; 13: 134-140
        • Jin C.
        • Hu Y.
        • Chen X.C.
        • Zheng F.Y.
        • Lin F.
        • Zhou K.
        • et al.
        Laparoscopic versus open myomectomy – a meta-analysis of randomized controlled trials.
        Eur J Obstet Gynecol Reprod Biol. 2009; 145: 14-21
        • Holzer A.
        • Jirecek S.T.
        • Illievich U.M.
        • Huber J.
        • Wenzl R.J.
        Laparoscopic versus open myomectomy: a double-blind study to evaluate postoperative pain.
        Anesth Analg. 2006; 102: 1480-1484
        • Alessandri F.
        • Lijoi D.
        • Mistrangelo E.
        • Ferrero S.
        • Ragni N.
        Randomized study of laparoscopic versus minilaparotomic myomectomy for uterine myomas.
        J Minim Invasive Gynecol. 2006; 13: 92-97
        • Malzoni M.
        • Tinelli R.
        • Cosentino F.
        • Iuzzolino D.
        • Surico D.
        • Reich H.
        Laparoscopy versus minilaparotomy in women with symptomatic uterine myomas: short-term and fertility results.
        Fertil Steril. 2010; 93: 2368-2373
        • Sinha R.
        • Hegde A.
        • Warty N.
        • Patil N.
        Laparoscopic excision of very large myomas.
        J Am Assoc Gynecol Laparosc. 2003; 10: 461-468
        • Vilos G.A.
        • Ternamian A.
        • Dempster J.
        • Laberge P.Y.
        Society of Obstetricians and Gynaecologists of Canada Clinical Practice Gynaecology Committee. Laparoscopic entry: a review of techniques, technologies, and complications.
        J Obstet Gynaecol Can. 2007; 29 (SOGC Clinical Practice Guidelines, No. 193, May 2007): 433-465
        • Lemyre M.
        • Bujold E.
        • Lathi R.
        • Bhagan L.
        • Huang J.Q.
        • Nezhat C.
        Comparison of morbidity associated with laparoscopic myomectomy and hysterectomy for the treatment of uterine leiomyomas.
        J Obstet Gynaecol Can. 2012; 34: 57-62
        • Gyamfi-Bannerman C.
        • Gilbert S.
        • Landon M.B.
        • Spong C.Y.
        • Rouse D.J.
        • Varner M.W.
        • et al.
        Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Risk of uterine rupture and placenta accreta with prior uterine surgery outside of the lower segment.
        Obstet Gynecol. 2012; 120: 1332-1337
        • Kumakiri J.
        • Takeuchi H.
        • Itoh S.
        • Kitade M.
        • Kikuchi I.
        • Shimanuki H.
        • et al.
        Prospective evaluation for the feasibility and safety of vaginal birth after laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2008; 15: 420-424
        • Seracchioli R.
        • Manuzzi L.
        • Vianello F.
        • Gualerzi B.
        • Savelli L.
        • Paradisi R.
        • et al.
        Obstetric and delivery outcome of pregnancies achieved after laparoscopic myomectomy.
        Fertil Steril. 2006; 86: 159-165
        • Seinera P.
        • Arisio R.
        • Decko A.
        • Farina C.
        • Crana F.
        Laparoscopic myomectomy: indications, surgical technique and complications.
        Hum Reprod. 1997; 12: 1927-1930
        • Parker W.H.
        • Einarsson J.
        • Istre O.
        • Dubuisson J.B.
        Risk factors for uterine rupture after laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2010; 17: 551-554
        • Dicle O.
        • Kücükler C.
        • Pirnar T.
        • Erata Y.
        • Posaci C.
        Magnetic resonance imaging evaluation of incision healing after cesarean sections.
        Eur Radiol. 1997; 7: 31-34
        • Seracchioli R.
        • Rossi S.
        • Govoni F.
        • Rossi E.
        • Venturoli S.
        • Bulletti C.
        • et al.
        Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: a randomized comparison with abdominal myomectomy.
        Hum Reprod. 2000; 15: 2663-2668
        • Hurst B.S.
        • Matthew M.L.
        • Marshburn P.B.
        Laparoscopic myomectomy for symptomatic uterine myomas.
        Fertil Steril. 2005; 83: 1-23
        • Prapas Y.
        • Kalogiannidis I.
        • Prapas N.
        Laparoscopy vs laparoscopically assisted myomectomy in the management of uterine myomas: a prospective study.
        Am J Obstet Gynecol. 2009; 200: 144-146
        • Wright J.D.
        • Ananth C.V.
        • Lewin S.N.
        • Burke W.M.
        • Lu Y.S.
        • Neugut A.I.
        • et al.
        Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.
        JAMA. 2013; 309: 689-698
        • Gargiulo A.R.
        • Srouji S.S.
        • Missmer S.A.
        • Correia K.F.
        • Vellinga T.
        • Einarsson J.I.
        Robot-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy.
        Obstet Gynecol. 2012; 120: 284-291
        • Liu H.
        • Lu D.
        • Wang L.
        • Shi G.
        • Song H.
        • Clarke J.
        Robotic surgery for benign gynaecological disease.
        Cochrane Database Syst Rev. 2012; 2 (CD008978)
        • AAGL Advancing Minimally Invasive Gynecology Worldwide
        AAGL position statement: robotic-assisted laparoscopic surgery in benign gynecology.
        J Min Invasiv Gynecol. 2013; 20: 2-9
        • Milad M.
        • Milad E.
        Laparoscopic morcellator-related complications.
        J Min Invas Gynecol. 2014; 21: 486-491
        • Sizzi O.
        • Rossetti A.
        • Malzoni M.
        • Minelli L.
        • La Grotta F.
        • Soranna L.
        • et al.
        Italian multicenter study on complications of laparoscopic myomectomy.
        J Minim Invasive Gynecol. 2007; 14: 453-462
        • Cucinella G.
        • Granese R.
        • Calagna G.
        • Somigliana E.
        • Perino A.
        Parasitic myomas after laparoscopic surgery: an emerging complication in the use of morcellator? Description of four cases.
        Fertil Steril. 2011; 96: e90-e96
        • Hilger W.S.
        • Magrina J.F.
        Removal of pelvic leiomyomata and endometriosis five years after supracervical hysterectomy.
        Obstet Gynecol. 2006; 108: 772-774
        • Hutchins Jr., F.L.
        • Reinoehl E.M.
        Retained myoma after laparoscopic supracervical hysterectomy with morcellation.
        J Am Assoc Gynecol Laparosc. 1998; 5: 293-295
        • Ordulu Z.
        • Dal Cin P.
        • Chong W.W.S.
        • Choy K.W.
        • Lee C.
        • Muto M.G.
        • et al.
        Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.
        Genes Chromosomes Cancer. 2010; 49: 1152-1160
        • Sinha R.
        • Sundaram M.
        • Mahajan C.
        • Sambhus A.
        Multiple leiomyomas after laparoscopic hysterectomy: report of two cases.
        J Minim Invasive Gynecol. 2007; 14: 123-127
        • Worthington-Kirsch R.
        • Hutchins Jr., F.J.
        Retained myoma fragment after LASH procedure.
        Clin Radiol. 2001; 56: 777-778
        • Sihna R.
        • Sundaran M.
        • Lakhotia S.
        Recurrent leiomyomatosis.
        J Min Invas Gynecol. 2009; 16 (8): 668
        • Ribič-Pucelj M.
        • Cvjetićanin B.
        • Šalamun V.
        Leiomyomatosis peritonealis disseminata as a possible result of laparoscopic myomectomy—report of four cases.
        Gynecol Surg. 2013; 10: 253-256
        • Amercian Cancer Society
        Survival rates for uterine sarcoma, by stage. American Cancer Society, Atlanta, GA2014 (Available at) (Accessed on November 11, 2014)
        • Health Canada
        Laparoscopic electric morcellators - risk of spread of unsuspected uterine sarcoma - notice to hospitals. Health Canada, Ottawa2014 (Available at) (Accessed on November 11, 2014)
        • Society of Gynecologic Oncology
        SGO position statement: morcellation. SGO, Chicago2013 (Available at) (Accessed on November 11, 2014)
        • AAGL Advancing Minimally Invasive Gynecology Worldwide
        Morcellation during uterine tissue extraction.
        J Minim Invasive Gynecol. 2014; 21: 517-530
        • American College of Obstetricians and Gynecologists
        Power morcellation and occult malignancy in gynecologic surgery. ACOG, Washington, DC2014 (Available at) (Accessed on November 22, 2014)
        • Food and Drug Administration
        Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids: summary and key findings. FDA, Silver Spring, MD2014 (Available at) (Accesssed on November 11, 2014)
        • Mussalam K.M.
        • Tamim H.M.
        • Richards T.
        • Spahn D.R.
        • Rosendaal F.R.
        • Habbal A.
        • et al.
        Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study.
        Lancet. 2011; 378 (9800): 1396-1407
        • Lethaby A.
        • Vollenhoven B.
        • Sowter M.
        Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
        Cochrane Database Syst Rev. 2001; 2 (CD000547)
        • Chen I.
        • Motan T.
        • Kiddoo D.
        Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials.
        J Minim Invasive Gynecol. 2011; 18: 303-309
        • De Falco M.
        • Staibano S.
        • Mascolo M.
        • Mignogna C.
        • Improda L.
        • Ciociola F.
        • et al.
        Leiomyoma pseudocapsule after pre-surgical tratment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes.
        Eur J Obstet Gynecol Reprod Biol. 2009; 144: 44-47
        • Mavrelos D.
        • Ben-Nagi J.
        • Davies A.
        • Lee C.
        • Salim R.
        • Jurkovic D.
        The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial.
        Hum Reprod. 2010; 25: 2264-2269
        • Chang F.W.
        • Yu M.H.
        • Ku C.H.
        • Chen C.H.
        • Wu G.J.
        • Liu J.Y.
        Effect of uterotonics on intra-operative blood loss during laparoscopy-assisted vaginal hysterectomy: a randomised controlled trial.
        BJOG. 2006; 113: 47-52
        • Celik H.
        • Sapmaz E.
        Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal myomectomy.
        Fertil Steril. 2003; 79: 1207-1210
        • Frederick S.
        • Frederick J.
        • Fletcher H.
        • Reid M.
        • Hardie M.
        • Gardner W.
        A trial comparing the use of rectal misoprostol plus perivascular vasopressin with perivascular vasopressin alone to decrease myometrial bleeding at the time of abdominal myomectomy.
        Fertil Steril. 2013; 100: 1044-1049
        • Preutthipan S.
        • Herabutya Y.
        Vaginal misoprostol for cervical priming before operative hysteroscopy: a randomized controlled trial.
        Obstet Gynecol. 2000; 96: 890-894
        • Cesen-Cummings K.
        • Houston K.D.
        • Copland J.A.
        • Moorman V.J.
        • Walker C.L.
        • Davis B.J.
        Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling.
        J Soc Gynecol Investig. 2003; 10: 11-20
        • Wang C.J.
        • Yuen L.T.
        • Yen C.F.
        • Lee C.L.
        • Soong Y.K.
        A simplified method to decrease operative blood loss in laparoscopic-assisted vaginal hysterectomy for the large uterus.
        J Am Assoc Gynecol Laparosc. 2004; 11: 370-373
        • Kongnyuy E.J.
        • Wiysonge C.S.
        Interventions to reduce haemorrhage during myomectomy for fibroids.
        Cochrane Database Syst Rev. 2011; 11 (CD005355)
        • Riess M.L.
        • Ulrichs J.G.
        • Pagel P.S.
        • Woehlck H.J.
        Case report: severe vasospasm mimics hypotension after high-dose intrauterine vasopressin.
        Anesth Analg. 2011; 113: 1103-1105
        • Okin C.R.
        • Guido R.S.
        • Meyn L.A.
        • Ramanathan S.
        Vasopressin during abdominal hysterectomy: a randomized controlled trial.
        Obstet Gynecol. 2001; 97: 867-872
        • Ginsburg E.S.
        • Benson C.B.
        • Garfield J.M.
        • Gleason R.E.
        • Friedman A.J.
        The effect of operative technique and uterine size on blood loss during myomectomy: a prospective randomized study.
        Fertil Steril. 1993; 60: 956-962
        • Fletcher H.
        • Frederick J.
        • Hardie M.
        • Simeon D.
        A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy.
        Obstet Gynecol. 1996; 87: 1014-1018
        • Zhao F.
        • Jiao Y.
        • Guo Z.
        • Hou R.
        • Wang M.
        Evaluation of loop ligation of larger myoma pseudocapsule combined with vasopressin on laparoscopic myomectomy.
        Fertil Steril. 2011; 95: 762-766
        • Zullo F.
        • Palomba S.
        • Corea D.
        • Pellicano M.
        • Russo T.
        • Falbo A.
        • et al.
        Bupivacaine plus epinephrine for laparoscopic myomectomy: a randomized placebo-controlled trial.
        Obstet Gynecol. 2004; 104: 243-249
        • Wellington K.
        • Wagstaff A.J.
        Tranexamic acid: a review of its use in the management of menorrhagia.
        Drugs. 2003; 63: 1417-1433
        • Caglar G.S.
        • Tasci Y.
        • Kayikcioglu F.
        • Haberal A.
        Intravenous tranexamic acid use in myomectomy: a prospective randomized double-blind placebo controlled study.
        Eur J Obstet Gynecol Reprod Biol. 2008; 137: 227-231
        • Bae J.H.
        • Chong G.O.
        • Seong W.J.
        • Hong D.G.
        • Lee Y.S.
        Benefit of uterine artery ligation in laparoscopic myomectomy.
        Fertil Steril. 2011; 95: 775-778
        • Chang W.C.
        • Huang P.S.
        • Wang P.H.
        • Chang D.Y.
        • Huang S.C.
        • Chen S.Y.
        • et al.
        Comparison of laparoscopic myomectomy using in situ morcellation with and without uterine artery ligation for treatment of symptomatic myomas.
        J Minim Invasive Gynecol. 2012; 19: 715-721
        • Ikechebelu J.I.
        • Ezeama C.O.
        • Obiechina N.J.
        The use of tourniquet to reduce blood loss at myomectomy.
        Niger J Clin Pract. 2010; 13: 154-158
        • Taylor A.
        • Sharma M.
        • Tsirkas P.
        • Di Spiezio Sardo A.
        • Setchell M.
        • Magos A.
        Reducing blood loss at open myomectomy using triple tourniquets: a randomised controlled trial.
        BJOG. 2005; 112: 340-345
        • Tinelli A.
        • Malvasi A.
        • Guido M.
        • Tsin D.A.
        • Hudelist G.
        • Hurst B.
        • et al.
        Adhesion formation after intracapsular myomectomy with or without adhesion barrier.
        Fertil Steril. 2011; 95: 1780-1785
        • Mettler L.
        • Hucke J.
        • Bojahr B.
        • Tinneberg H.R.
        • Leyland N.
        • Avelar R.
        A safety and efficacy study of a resorbable hydrogel for reduction of post-operative adhesions following myomectomy.
        Hum Reprod. 2008; 23: 1093-1100
        • Takeuchi H.
        • Kitade M.
        • Kikuchi I.
        • Shimanuki H.
        • Kumakiri J.
        • Kinoshita K.
        Adhesion-prevention effects of fibrin sealants after laparoscopic myomectomy as determined by second-look laparoscopy: a prospective, randomized, controlled study.
        J Reprod Med. 2005; 50: 571-577
        • Lefebvre G.G.
        • Vilos G.
        • Asch M.
        Society of Obstetricians and Gynaecologists of Canada; Canadian Association of Radiologists; Canadian Interventional Radiology Association. Uterine fibroid embolization (UFE).
        J Obstet Gynaecol Can. 2004; 26 (SOGC Clinical Practice Guidelines, No. 150, October 2004): 913-928
        • Pron G.
        • Mocarski E.
        • Bennett J.
        • Vilos G.
        • Common A.
        • Vanderburgh L.
        • Ontario U.F.E.
        • Group Collaborative
        Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial.
        Obstet Gynecol. 2005; 105: 67-76
        • Mara M.
        • Kubinova K.
        Embolization of uterine fibroids from the point of view of the gynecologist: pros and cons.
        Int J Womens Health. 2014; 6: 623-629
        • Martin J.
        • Bhanot K.
        • Athreya S.
        Complications and reinterventions in uterine artery embolization for symptomatic uterine fibroids: a literature review and meta-analysis.
        Cardiovasc Intervent Radiol. 2013; 36: 395-402
        • Zupi E.
        • Sbracia M.
        • Marconi D.
        • Munro M.G.
        Myolysis of uterine fibroids: is there a role?.
        Clin Obstet Gynecol. 2006; 49: 821-833
        • National Institute for Health and Clinical Excellence (NICE)
        IPG 413: magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids. NICE, London2014 (Available at) (Accessed on November 11, 2014)
        • Ghezzi F.
        • Cromi A.
        • Bergamini V.
        • Scarperi S.
        • Bolis P.
        • Franchi M.
        Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas.
        Surg Endosc. 2007; 21: 2081-2085
        • Pansky M.
        • Cowan B.D.
        • Frank M.
        • Hampton H.L.
        • Zimberg S.
        Laparoscopically assisted uterine fibroid cryoablation.
        Am J Obstet Gynecol. 2009; 201: 571-577
        • Bourlev V.
        • Pavlovitch S.
        • Stygar D.
        • Volkov N.
        • Lindblom B.
        • Olovsson M.
        Different proliferative and apoptotic activity in peripheral versus central parts of human uterine leiomyomas.
        Gynecol Obstet Invest. 2003; 55: 199-204
        • Bouwsma E.V.
        • Hesley G.K.
        • Woodrum D.A.
        • Weaver A.L.
        • Leppert P.C.
        • Peterson L.G.
        • et al.
        Comparing focused ultrasound and uterine artery embolization for uterine fibroids-rationale and design of the Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) trial.
        Fertil Steril. 2011; 96: 704-710
        • Bouwsma E.V.
        • Gorny K.R.
        • Hesley G.K.
        • Jensen J.R.
        • Peterson L.G.
        • Stewart E.A.
        Magnetic resonance-guided focused ultrasound surgery for leiomyoma-associated infertility.
        Fertil Steril. 2011; 96: e9-e12
        • Chudnoff S.G.
        • Berman J.M.
        • Levine D.J.
        • Harris M.
        • Guido R.S.
        • Banks E.
        Outpatient procedure for the treatment and relief of symptomatic uterine myomas.
        Obstet Gynecol. 2013; 121: 1075-1082
        • Munro M.G.
        Southern California Permanente Medical Group’s Abnormal Uterine Bleeding Working Group. Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.
        Perm J. 2013; 17: 43-56
        • Friedman A.J.
        Combined oestrogen-progestin treatment of vaginal hemorrhage following gonadotropin-releasing hormone agonist therapy of uterine myomas.
        Hum Reprod. 1993; 8: 540-542
        • Thomas M.A.
        • Gass M.L.
        • Scott M.C.
        • Liu J.H.
        Multiple therapies for vaginal bleeding secondary to large uterine myomas.
        Int J Gynaecol Obstet. 1991; 36: 239-241
        • Lakhani K.P.
        • Marsh M.S.
        • Purcell W.
        • Hardiman P.
        Uterine artery blood flow parameters in women with dysfunctional uterine bleeding and uterine fibroids: the effects of tranexamic acid.
        Ultrasound Obstet Gynecol. 1998; 11: 23-28
        • Lukes A.S.
        • Moore K.A.
        • Muse K.N.
        • Gersten J.K.
        • Hecht B.R.
        • Edlund M.
        • et al.
        Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial.
        Obstet Gynecol. 2010; 116: 865-875
        • Naoulou B.
        • Tsai M.C.
        Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review.
        Acta Obstet Gynecol Scand. 2012; 91: 529-537
        • Lindoff C.
        • Rybo G.
        • Astedt B.
        Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
        Thromb Haemost. 1993; 70: 238-240
        • Sundstrom A.
        • Seaman H.
        • Kieler H.
        • Alfredsson L.
        The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database.
        BJOG. 2009; 116: 91-97
        • Donnez J.
        • Tomaszewski J.
        • Vazquez F.
        • Bouchard P.
        • Lemieszczuk B.
        • Baro F.
        • et al.
        Ulipristal acetate versus leuprolide acetate for uterine fibroids.
        N Engl J Med. 2012; 366: 421-432
        • Hamani Y.
        • Ben-Shachar I.
        • Kalish Y.
        • Porat S.
        Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding.
        Fertil Steril. 2010; 94 (2769): e13-e15
        • Goldrath M.H.
        Uterine tamponade for the control of acute uterine bleeding.
        Am J Obstet Gynecol. 1983; 147: 869-872
        • Thorp J.M.
        • Katz V.L.
        Submucous myomas treated with gonadotropin releasing hormone agonist and resulting in vaginal hemorrhage. A case report.
        J Reprod Med. 1991; 36: 625-626
        • Richards S.R.
        Endometrial ablation for life-threatening abnormal uterine bleeding. A report of two cases.
        J Reprod Med. 1994 Sep; 39: 741-742
        • Osuga Y.
        • Okagaki R.
        • Ozaki S.
        • Matsumi H.
        • Fujii T.
        • Iwase H.
        • et al.
        Successful emergency endometrial ablation for intractable uterine bleeding in a postmenopausal woman complicated with liver cirrhosis and morbid obesity.
        Surg Endosc. 2001; 15: 898
        • Woolf S.H.
        • Battista R.N.
        • Angerson G.M.
        • Logan A.G.
        • Eel W.
        Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care.
        CMAJ. 2003; 169: 207-208